<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Latin America</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Mexico’s COFEPRIS adds SaMD to definitions in revised labeling rule</title>
      <description>
        <![CDATA[Mexico’s Federal Commission for Protection Against Sanitary Risk (COFEPRIS) has released a draft proposal that would overhaul the 2008 version of the rule for device labeling, a document that includes several key proposed reforms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708205</guid>
      <pubDate>Tue, 07 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708205-mexicos-cofepris-adds-samd-to-definitions-in-revised-labeling-rule</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Regulatory-icons.webp?t=1680727865" type="image/png" medium="image" fileSize="30365">
        <media:title type="plain">Regulatory icons </media:title>
      </media:content>
    </item>
    <item>
      <title>Brazil’s new medical device rules starting in March promise to simplify process</title>
      <description>
        <![CDATA[Brazilian health care regulator Anvisa unveiled new medical device rules that promise to simplify over two decades of accumulated directives, putting into force changes announced by the health care surveillance agency in 2022.]]>
      </description>
      <guid>http://www.bioworld.com/articles/693622</guid>
      <pubDate>Wed, 25 Jan 2023 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/693622-brazils-new-medical-device-rules-starting-march-promise-to-simplify-process</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/South-America/Brazil-flag.webp?t=1588688582" type="image/png" medium="image" fileSize="472983">
        <media:title type="plain">Brazilian flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Proxalutamide study once again in Brazilian crosshairs</title>
      <description>
        <![CDATA[Brazilian regulatory agency Anvisa reported that it is participating in an investigation that launched Aug. 25 into alleged crimes of smuggling, misrepresenting, distributing and delivering proxalutamide related to a clinical trial in Brazil.]]>
      </description>
      <guid>http://www.bioworld.com/articles/523394</guid>
      <pubDate>Tue, 30 Aug 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/523394-proxalutamide-study-once-again-in-brazilian-crosshairs</link>
    </item>
    <item>
      <title>Companies race to conquer the Monkeypox IVD market in Brazil</title>
      <description>
        <![CDATA[Five companies have applied for marketing authorizations in Brazil to deliver rapid test kits to diagnose monkeypox cases in real time.]]>
      </description>
      <guid>http://www.bioworld.com/articles/521922</guid>
      <pubDate>Thu, 25 Aug 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/521922-companies-race-to-conquer-the-monkeypox-ivd-market-in-brazil</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/South-America/Brazil-flag.webp?t=1588688582" type="image/png" medium="image" fileSize="472983">
        <media:title type="plain">Brazilian flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Henlius establishing big biosimilar deals in Latin America</title>
      <description>
        <![CDATA[Two major deals inked by Shanghai Henlius Biotech Inc. in May confirm the company’s plans to invest heavily in the Latin American market. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/519525</guid>
      <pubDate>Tue, 07 Jun 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519525-henlius-establishing-big-biosimilar-deals-in-latin-america</link>
    </item>
    <item>
      <title>Henlius establishing big biosimilar deals in Latin America</title>
      <description>
        <![CDATA[Two major deals inked by Shanghai Henlius Biotech Inc. in May confirm the company’s plans to invest heavily in the Latin American market. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/519356</guid>
      <pubDate>Wed, 01 Jun 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519356-henlius-establishing-big-biosimilar-deals-in-latin-america</link>
    </item>
    <item>
      <title>Brazil readies to adopt SaMD regulation</title>
      <description>
        <![CDATA[Brazil’s health care regulator plans to start enforcing in July new regulations for software as a medical device (SaMD), clearing up doubts about its oversight over intangible health care assets such as software.]]>
      </description>
      <guid>http://www.bioworld.com/articles/519257</guid>
      <pubDate>Fri, 27 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519257-brazil-readies-to-adopt-samd-regulation</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/South-America/Brazil-flag.webp?t=1588688582" type="image/png" medium="image" fileSize="472983">
        <media:title type="plain">Brazilian flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Nugen sets its sights on US and Mexican type 1 diabetes markets</title>
      <description>
        <![CDATA[A needle-free injection system for patients with diabetes developed by Nugen Medical Devices Inc. has been approved for use in 40 countries but until now has yet to crack the North American market. Nugen said it is now gearing up for FDA and Mexican approval of the Nugen MD needle-free injector following Health Canada’s approval of the system less than a month after the Toronto med tech went public in late 2021.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516457</guid>
      <pubDate>Fri, 25 Feb 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516457-nugen-sets-its-sights-on-us-and-mexican-type-1-diabetes-markets</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/02-25-nugen-device.webp?t=1645828913" type="image/png" medium="image" fileSize="1908360">
        <media:title type="plain">Nugen device in use</media:title>
        <media:description type="plain">Spring-loaded and virtually pain-free, the Nugen MD passes insulin through a hole at the end of the syringe about the size of a human hair to accelerate uptake of the life saving drug.</media:description>
      </media:content>
    </item>
    <item>
      <title>Latin America’s med-tech sector faces steep hurdles</title>
      <description>
        <![CDATA[The med-tech industry across Latin America continues to grow, but the growth is uneven, concentrated in a handful of countries and faces significant challenges. A report released in December by the United Nations Economic Commission for Latin America and the Caribbean (ECLAC) reveals the complexity of the region's med-tech trade balance and underscores the main challenges for the industry in the region, whose performance was also impacted by the COVID-19 pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514730</guid>
      <pubDate>Fri, 31 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514730-latin-americas-med-tech-sector-faces-steep-hurdles</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/South-America/latin-america-south-america.webp?t=1588688712" type="image/png" medium="image" fileSize="675661">
        <media:title type="plain">Map of Latin America, South America</media:title>
      </media:content>
    </item>
    <item>
      <title>Promising results drive push for Paxlovid compulsory license</title>
      <description>
        <![CDATA[Although Pfizer Inc.’s COVID-19 oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), has yet to be authorized anywhere, the push for compulsory licensing of the drug has begun.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514050</guid>
      <pubDate>Tue, 07 Dec 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514050-promising-results-drive-push-for-paxlovid-compulsory-license</link>
    </item>
    <item>
      <title>Med-tech innovations selected for The Royal Academy of Engineering’s LIF Advance program</title>
      <description>
        <![CDATA[The Royal Academy of Engineering in the U.K. has selected 15 entrepreneurs from seven different countries for the latest edition of its Leaders in Innovation Fellowships Advance (LIF Advance) program, including some that offer med-tech solutions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514002</guid>
      <pubDate>Mon, 06 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514002-med-tech-innovations-selected-for-the-royal-academy-of-engineerings-lif-advance-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/newco-idea-hand-holding-lighbulb.webp?t=1588277852" type="image/png" medium="image" fileSize="376409">
        <media:title type="plain">Hand holding lightbulb</media:title>
      </media:content>
    </item>
    <item>
      <title>Tired of waiting for vaccines, PAHO proposes making its own</title>
      <description>
        <![CDATA[With the Americas having the dubious distinction of the most COVID-19 cases in the world, the Pan American Health Organization (PAHO) is answering that “wake-up call” with plans to develop a collaborative platform to develop mRNA vaccine production in Latin America and the Caribbean.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510837</guid>
      <pubDate>Thu, 26 Aug 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510837-tired-of-waiting-for-vaccines-paho-proposes-making-its-own</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Vaccine-production.webp?t=1617391669" type="image/png" medium="image" fileSize="495496">
        <media:title type="plain">Pharmaceutical vial manufacturing</media:title>
      </media:content>
    </item>
    <item>
      <title>Celltrion wins Anvisa approval for COVID-19 antibody in first nod outside Asia</title>
      <description>
        <![CDATA[Celltrion Inc. has bagged its first green light outside Asia for its COVID-19 monoclonal antibody Regkirona (regdanvimab) with an emergency use authorization in Brazil. Brazil’s Anvisa gave the EUA for the drug to treat high-risk adult patients, including those aged 65 or older, with mild and moderate COVID-19 symptoms on Aug. 11. The regulator reached its decision on the drug, also known as CT-P59, via a unanimous vote.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510533</guid>
      <pubDate>Tue, 17 Aug 2021 16:16:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510533-celltrion-wins-anvisa-approval-for-covid-19-antibody-in-first-nod-outside-asia</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWA-source/2021/Celltrion-Regkirona-2-9.webp?t=1623696372" type="image/png" medium="image" fileSize="696881">
        <media:title type="plain">Celltrion-Regkirona-2-9</media:title>
        <media:description type="plain">Credit: Celltrion Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Celltrion wins Anvisa approval for COVID-19 antibody in first nod outside Asia</title>
      <description>
        <![CDATA[Celltrion Inc. has bagged its first green light outside Asia for its COVID-19 monoclonal antibody Regkirona (regdanvimab) with an emergency use authorization in Brazil. Brazil’s Anvisa gave the EUA for the drug to treat high-risk adult patients, including those aged 65 or older, with mild and moderate COVID-19 symptoms on Aug. 11. The regulator reached its decision on the drug, also known as CT-P59, via a unanimous vote. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/510376</guid>
      <pubDate>Thu, 12 Aug 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510376-celltrion-wins-anvisa-approval-for-covid-19-antibody-in-first-nod-outside-asia</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWA-source/2021/Celltrion-Regkirona-2-9.webp?t=1623696372" type="image/png" medium="image" fileSize="696881">
        <media:title type="plain">Celltrion-Regkirona-2-9</media:title>
        <media:description type="plain">Credit: Celltrion Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Argentine startup prepares to screen up to 20M probes</title>
      <description>
        <![CDATA[Startup Aplife Biotech is tapping into the rapidly growing market for biosensors that can expand the capacity of hand-held devices to screen for thousands of pathologies from a single drop of blood. Using technology developed in Argentina to print DNA structures on microchips, the company&rsquo;s goal is to screen as many as 20 million probes with the potential to convert molecular interactions into electrical signals, opening a path for med-tech developers and manufacturers to explore new solutions for personalized health care.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507568</guid>
      <pubDate>Thu, 27 May 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507568-argentine-startup-prepares-to-screen-up-to-20m-probes</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/05-27-Aplife-printer.webp?t=1622143271" type="image/png" medium="image" fileSize="198675">
        <media:title type="plain">Aplife's DNA printer</media:title>
        <media:description type="plain">With its printer, Aplife wants to test find biomarkers to vastly expand the capacity of hand-held devices to screen for diseases. Credit: Aplife Biotech</media:description>
      </media:content>
    </item>
    <item>
      <title>Countries continue to push for access to COVID-19 technologies, challenges remain</title>
      <description>
        <![CDATA[As infections and deaths continue to surge in some countries so does the demand for unfettered access to the technologies behind COVID-19 vaccines and other medical products. In seeking that access, several countries are stressing the need to develop their own manufacturing capacity as they look beyond the current pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507454</guid>
      <pubDate>Tue, 25 May 2021 15:04:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507454-countries-continue-to-push-for-access-to-covid-19-technologies-challenges-remain</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Vaccine-production.webp?t=1617391669" type="image/png" medium="image" fileSize="495496">
        <media:title type="plain">Pharmaceutical vial manufacturing</media:title>
      </media:content>
    </item>
    <item>
      <title>Countries continue to push for access to COVID-19 technologies, challenges remain</title>
      <description>
        <![CDATA[As infections and deaths continue to surge in some countries so does the demand for unfettered access to the technologies behind COVID-19 vaccines and other medical products. In seeking that access, several countries are stressing the need to develop their own manufacturing capacity as they look beyond the current pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507332</guid>
      <pubDate>Thu, 20 May 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507332-countries-continue-to-push-for-access-to-covid-19-technologies-challenges-remain</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Vaccine-production.webp?t=1617391669" type="image/png" medium="image" fileSize="495496">
        <media:title type="plain">Pharmaceutical vial manufacturing</media:title>
      </media:content>
    </item>
    <item>
      <title>Brazilian and European regulators agree to share confidential information</title>
      <description>
        <![CDATA[For almost two months, Brazil&rsquo;s health care surveillance agency Anvisa, the European Medicines Agency, and the Directorate-General for Health and Food Safety have been sharing regulatory and confidential information as part of an effort to improve the safety and efficacy of drugs and medical devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507147</guid>
      <pubDate>Mon, 17 May 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507147-brazilian-and-european-regulators-agree-to-share-confidential-information</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake_global2.webp?t=1588276797" type="image/png" medium="image" fileSize="557443">
        <media:title type="plain">Handshake behind digital globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Brazilian and European regulators agree to share confidential information</title>
      <description>
        <![CDATA[For almost two months, Brazil&rsquo;s health care surveillance agency Anvisa, the European Medicines Agency (EMA), and the Directorate-General for Health and Food Safety have been sharing regulatory and confidential information as part of an effort to improve the safety and efficacy of drugs and medical devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507107</guid>
      <pubDate>Fri, 14 May 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507107-brazilian-and-european-regulators-agree-to-share-confidential-information</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake_global2.webp?t=1588276797" type="image/png" medium="image" fileSize="557443">
        <media:title type="plain">Handshake behind digital globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Three-shot Cuban COVID-19 vaccine candidate moves forward in phase III</title>
      <description>
        <![CDATA[CAJICA, Colombia – Following the start of phase III trials for its COVID-19 vaccine, Soberana 02, Cuban researchers have started phase III trials for Abdala (CIGB-66), another vaccine candidate developed in the island country.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505740</guid>
      <pubDate>Fri, 09 Apr 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505740-three-shot-cuban-covid-19-vaccine-candidate-moves-forward-in-phase-iii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/South-America/Cuba-flag.webp?t=1617993634" type="image/png" medium="image" fileSize="380600">
        <media:title type="plain">Cuban flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Costa Rica leads Central America in med-tech production, exports</title>
      <description>
        <![CDATA[CAJICA, Colombia &ndash; The tiny Central American country of Costa Rica continues to cement its position as Latin America&rsquo;s med-tech powerhouse after experiencing double-digit growth in exports in the first two months of the year, according to data released by Procomer, the country&#39;s exports promotion agency. &ldquo;These numbers become more relevant when detailing that medical devices and precision equipment represent, for the third consecutive year, the country&#39;s main export, which had double-digit growth of 23%, thus representing 36% of the exports of the country,&rdquo; the Costa Rican government said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505496</guid>
      <pubDate>Fri, 02 Apr 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505496-costa-rica-leads-central-america-in-med-tech-production-exports</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/South-America/costa-rica-economy-flag.webp?t=1588688668" type="image/png" medium="image" fileSize="1689009">
        <media:title type="plain">Costa Rican flag, economy/growth puzzle pieces</media:title>
      </media:content>
    </item>
    <item>
      <title>Mixed decisions about Astrazeneca’s SARS-CoV-2 vaccine in Latin America</title>
      <description>
        <![CDATA[CAJICA, Colombia – Countries in Latin America have joined those in Europe expressing mixed reactions about continuing their vaccination plans with the AZD-1222 SARS-CoV-2 vaccine developed by Astrazeneca plc and the University of Oxford, following reports of alleged adverse events.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505078</guid>
      <pubDate>Tue, 23 Mar 2021 14:15:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505078-mixed-decisions-about-astrazenecas-sars-cov-2-vaccine-in-latin-america</link>
    </item>
    <item>
      <title>COVID-19 reveals continuing issues with tracking of med tech in Mexico</title>
      <description>
        <![CDATA[CAJICA, Colombia &ndash; The COVID-19 pandemic has exposed the weaknesses of Mexico&rsquo;s techno-vigilance system, along with a chronic lack of reporting of inventories and adverse effects related to medical devices in use. These weaknesses were exposed during previous pandemics but the country&rsquo;s antiquated tracking and reporting system has not changed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505087</guid>
      <pubDate>Tue, 23 Mar 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505087-covid-19-reveals-continuing-issues-with-tracking-of-med-tech-in-mexico</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/South-America/Mexico-map-magnifying-glass.webp?t=1632866861" type="image/png" medium="image" fileSize="1610966">
        <media:title type="plain">Magnifying glass over globe, focused on Mexico</media:title>
        <media:description type="plain">Credit: sharafmaksumov - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Mixed decisions about Astrazeneca’s SARS-CoV-2 vaccine in Latin America</title>
      <description>
        <![CDATA[CAJICA, Colombia – Countries in Latin America have joined those in Europe expressing mixed reactions about continuing their vaccination plans with the AZD-1222 SARS-CoV-2 vaccine developed by Astrazeneca plc and the University of Oxford, following reports of alleged adverse events.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504965</guid>
      <pubDate>Fri, 19 Mar 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/504965-mixed-decisions-about-astrazenecas-sars-cov-2-vaccine-in-latin-america</link>
    </item>
    <item>
      <title>Cuba’s Soberana 02 SARS-CoV-2 vaccine candidate moves to phase III trials</title>
      <description>
        <![CDATA[CAJICA, Colombia – Cuba’s Center for the State Control of Drugs, Equipment and Medical Devices gave the green light March 3 for phase III trials of a domestically developed COVID-19 vaccine candidate, even though very little peer-reviewed information has been published about it.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504357</guid>
      <pubDate>Thu, 04 Mar 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504357-cubas-soberana-02-sars-cov-2-vaccine-candidate-moves-to-phase-iii-trials</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Cuba-mask-and-syringe.webp?t=1606319807" type="image/png" medium="image" fileSize="402211">
        <media:title type="plain">Cuba mask and syringe</media:title>
      </media:content>
    </item>
    <item>
      <title>Study identifies Brazil SARS-CoV-2 variant that can evade protective immunity</title>
      <description>
        <![CDATA[LONDON – The SARS-CoV-2 variant of concern that caused a wave of infection in Manaus, Brazil, in December and January has been found to be both more transmissible and to evade immunity conferred by prior natural infection with the virus. A combined Brazil/U.K. genome sequencing and epidemiological study found the variant, called P.1., is between 1.4 and 2.2 times more transmissible than earlier lineages, and can evade 25% to 61% of the protective immunity elicited by previous infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504302</guid>
      <pubDate>Wed, 03 Mar 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504302-study-identifies-brazil-sars-cov-2-variant-that-can-evade-protective-immunity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/South-America/Brazil-flag.webp?t=1588688582" type="image/png" medium="image" fileSize="472983">
        <media:title type="plain">Brazilian flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Study identifies Brazil SARS-CoV-2 variant that can evade protective immunity</title>
      <description>
        <![CDATA[LONDON – The SARS-CoV-2 variant of concern that caused a wave of infection in Manaus, Brazil, in December and January has been found to be both more transmissible and to evade immunity conferred by prior natural infection with the virus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504235</guid>
      <pubDate>Tue, 02 Mar 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504235-study-identifies-brazil-sars-cov-2-variant-that-can-evade-protective-immunity</link>
    </item>
    <item>
      <title>COVID-19 pandemic charges Latin American med-tech sector</title>
      <description>
        <![CDATA[CAJICA, Colombia &ndash; Three countries have emerged as the key engines of growth for Latin America&rsquo;s medical devices sector, accounting for the largest share of exports and investment in the space across the region and experiencing growth over the past decade that may have been supercharged by the COVID-19 pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504010</guid>
      <pubDate>Wed, 24 Feb 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/504010-covid-19-pandemic-charges-latin-american-med-tech-sector</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/South-America/latin-america-south-america.webp?t=1588688712" type="image/png" medium="image" fileSize="675661">
        <media:title type="plain">Map of Latin America, South America</media:title>
      </media:content>
    </item>
    <item>
      <title>Seegene strengthens footprint in Latin America via COVID testing</title>
      <description>
        <![CDATA[COLOMBIA &ndash; South Korea&rsquo;s molecular diagnostics firm Seegene Inc. is expanding operations in the Brazilian market after Anvisa, the country&#39;s health care surveillance agency, cleared its multi-assay product through a COVID-19 emergency pathway. Seegene manufactures Allplex, a SARS-CoV-2/FluA/FluB/RSV test able to screen and differentiate eight targets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503583</guid>
      <pubDate>Fri, 12 Feb 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503583-seegene-strengthens-footprint-in-latin-america-via-covid-testing</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/South-America/Mask-with-Brazilian-flag.webp?t=1600286615" type="image/png" medium="image" fileSize="385712">
        <media:title type="plain">Mask with Brazilian flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Colombia approves two more COVID-19 vaccine trials</title>
      <description>
        <![CDATA[CAJICA, Colombia - Colombia approved two different phase II/III trials for COVID-19 vaccine candidates over the last week, advancing one candidate developed by Germany’s Curevac AG and another by China’s Clover Biopharmaceuticals Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503176</guid>
      <pubDate>Wed, 03 Feb 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503176-colombia-approves-two-more-covid-19-vaccine-trials</link>
    </item>
  </channel>
</rss>
